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Abstract
We report three cases of ileocolic mucormycosis in 
adult immunocompromised patients presenting as 
acute abdomen. All patients underwent laparotomy but 
two of them died from multiorgan failure before the 
diagnoses were confirmed. The diagnosis of gastroin-
testinal mucormycosis is rarely suspected, and ante-
mortem diagnosis is made in only 25%-50% of cases. 
These cases illustrate the difficulty encountered by 
surgeons in managing acute abdomen in neutropenic 
patients with hematological malignancy. The manage-
ment of colonic mucormycosis in the published litera-
ture is also reviewed.
© 2010 Baishideng. All rights reserved.
Key words: Gastrointestinal mucormycosis; Colon; Immu-
nocompromised; Surgery
Peer reviewers: Dr. Benjamin Perakath, Professor, Department 
of Surgery Unit 5, Christian Medical College, Vellore 632004, 
Tamil Nadu, India; Venkatesh Shanmugam, MBBS, MS (Gen. 
Surg.), Dip.NB (Gen. Surg.), FRCS (Glasg.), MD, Specialist 
Registrar (Trent Deanery), Royal Derby Hospital, Uttoxeter 
Road, Derby, DE22 3NE, United Kingdom
Lo OSH, Law WL. Ileocolonic mucormycosis in adult im-
munocompromised patients: A surgeon’s perspective. World J 
Gastroenterol 2010; 16(9): 1165-1170  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v16/i9/1165.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v16.i9.1165
INTRODUCTION
Neutropenic patients can present with acute abdominal 
catastrophes of  various causes and surgical intervention 
is required. However, surgery is usually associated with 
a high mortality and morbidity in the immunocompro-
mised host. With the rising incidence of  invasive fungal 
infection in patients with hematological malignancy and 
transplant recipients, mucormycosis has been reported 
to be the third most common cause of  fungal infection 
after candidiasis and aspergillosis[1,2]. Mucormycosis re-
fers to several different diseases caused by Mucorales[3,4]. 
These rare infections usually only occur in individuals 
with impaired immunity, having associations with diabe-
tes mellitus, hematological or solid-organ malignancies, 
transplantation, neutropenia and steroid therapy. The 
diagnosis of  mucormycosis is rarely suspected and ante-
mortem diagnosis is made in only 25%-50% of  cases[5]. 
CASE REPORT
Case 1
A 42-year-old lady received chemotherapy for NK cell 
lymphoma and, concomitant with disease progression, 
she presented with ascites and pleural effusion. She com-
plained of  abdominal pain and fever in February 2009. 
Physical examination showed generalized tenderness and 
the aspirated peritoneal fluid was turbid. Laparotomy was 
undertaken for suspected perforated viscus. On laparot-
omy, the ascitic fluid was grossly turbid. The cecum was 
grossly dilated but no perforation was identified. The rest 
of  the laparotomy was grossly normal except for the in-
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flamed omentum which was densely adhered to the pelvic 
cavity. Peritoneal lavage with saline was the only procedure 
performed. Postoperatively, Tazocin, amikacin and vori-
conazole were given as Klebsiella, Escherichia coli and Candida 
albicans were identified from the peritoneal fluid. However, 
the patient’s condition rapidly deteriorated and she died 
two weeks after operation. The autopsy showed extensive 
involvement of  fungal elements inside the abdominal cav-
ity. Also, branching septate fungi were isolated in one of  
the peritoneal fluid cultures after the patient succumbed 
and later confirmed to be Rhizopus species.
Case 2
A 57-year-old man had relapsed diffuse large B-cell 
lymphoma and underwent palliative chemotherapy and 
radiotherapy. He presented with peritonitis in September 
2008. An urgent computer tomography (CT) scan of  the 
abdomen showed free intraperitoneal gas; emergency lap-
arotomy was undertaken and two 1-cm perforations with 
indurated edges were identified over the cecum. Ileocecal 
resection and end ileostomy were performed in view of  
gross peritoneal contamination. Histological examination 
showed lymphoma involving the colonic wall and causing 
the perforations. Broad-spectrum antibiotics (meropenem 
and vancomycin) and prophylactic fluconazole were given 
in view of  multiple bacteria shown in peritoneal fluid 
cultures. A well-demarcated gangrenous skin necrosis ap-
peared over the peristomal area and at the upper midline 
wound on day 8 (Figure 1). Finally, the patient died of  
multiorgan failure two days later. Subsequent wound swab 
culture revealed Rhizopus species. No autopsy was per-
formed because of  refusal by the family.
Case 3
A 38-year-old male, with persistent precursor B cell acute 
lymphoblastic leukemia, developed abdominal pain and 
fever on the eighth day after receiving clofarabine therapy 
in February 2009. An urgent abdominal CT scan showed 
features suggestive of  appendiceal abscess with suspected 
pneumoperitoneum. He underwent emergency laparoto-
my and was found to have gangrenous appendicitis with 
localized retrocecal abscess. Ileocecal resection and prima-
ry anastomosis were performed. Postoperatively, liposomal 
amphotericin, caspofungin and posaconazole were started 
immediately as the microbiologist identified Rhizopus 
species in the specimen. Granulocyte colony-stimulating 
factor was also prescribed for severe neutropenia. The pa-
tient recovered well and was transferred back to the gen-
eral ward. One week later, he still had persistent abdomi-
nal distension and developed deep venous thrombosis of  
the right lower limb. A abdominal CT scan showed that 
there was no contrast opacification at the right external 
iliac vessels and impaired contrast enhancement at the 
terminal ileum. Exploratory laparotomy was undertaken 
on day 12 after the first operation and multiple hardened 
fungal colonies were noted over the omentum and small 
bowel (Figure 2). An inflammatory mass compressed the 
right iliac vessels, causing decreased venous blood flow. 
A 20-cm segment of  small bowel proximal to the previ-
ous ileocolic anastomosis densely adhered to the previous 
operative site and was ischemic. Small bowel resection, 
end ileostomy and omentectomy were performed. Mul-
tiple patches of  full-thickness bowel ischemia were seen 
over the colonic wall (Figure 3) and mucormycosis was 
confirmed on histological examination. Though extensive 
surgical debridement and maximal medical support were 
administered, the patient died four days after the second 
laparotomy.
DISCUSSION
Mucormycosis is an opportunistic fungal infection 
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Figure 1  Dermal mucormycosis around ileostomy and laparotomy wound. Figure 2  Fungal colonies over omentum and small bowel surface.
Figure 3  Black ulcer with full bowel infarction at colon on exposed 
specimen.
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caused by fungi of  the order Mucorales[4]. However, it 
is often inappropriately interchanged with the term zy-
gomycosis (infection caused by the class Zygomycetes) 
in medical literature. The Zygomycetes are divided into 
two orders: the Entomophthorales, containing very rare 
pathogenic species; and the Mucorales, which contain 
the most common human pathogens, including Rhizopus, 
Mucor, Absidia, and Cunninghamellaceae (Table 1)[3,4]. Differ-
entiation among these species is based on the morphol-
ogy of  the asexual cycle, physiologic characteristics, and 
zygospore production. Nonetheless, they rarely cause 
disease because of  the low virulence of  the organisms 
and thus they mainly affect immunocompromised indi-
viduals. Novel immunosuppressive therapies and other 
advances in the understanding of  disease pathology and 
diagnosis have contributed to patients living longer with 
previously debilitating medical problems and impaired 
immune systems. 
The most common agent of  mucormycosis is the 
Rhizopus species, which is considerably more virulent 
than other fungi in the order. Similar to Aspergillus, the 
pathogenesis may be attributed to the tendency to be an-
gioinvasive (vasculotropism) as blood vessels are the best 
source of  oxygen, resulting in local ischemia, necrosis, 
and tissue infarction as well as providing the nidus for 
hematogenous dissemination[3]. Though being less clearly 
understood than for aspergillosis, several risk factors or 
predisposing conditions have been well described in the 
literature. In a large review of  929 patients with zygomy-
cosis[6], diabetes was the most common underlying risk 
factor (36%), followed by malignancy (17%), solid organ 
transplantation (7%), desferroxamine therapy (6%), and 
bone marrow transplantation (5%). Most of  these con-
ditions are associated with impairment of  normal leu-
kocyte immune function. Impairment of  this function 
or a critical decline in white cell number is associated 
with increased risk for invasive fungal infections. Apart 
from differences in environmental factors, changes in 
transplantation procedures, new use of  immunosuppres-
sives and the use of  voriconazole for the prophylaxis of  
opportunistic fungal infections have been proposed as 
risk factors for developing zygomycosis[7,8]. Voriconazole 
is not active against Zygomycetes and subsequently may 
provide selective growth of  these fungi. Breakthrough 
zygomycosis after voriconazole treatment has been re-
ported but the association is still uncertain[7,9].  
Mucormycosis can manifest as different clinical 
forms, namely rhinocerebral, pulmonary, cutaneous, 
gastrointestinal, central nervous system, and dissemi-
nated/miscellaneous. Gastrointestinal mucormycosis is 
the rarest form and constitutes only 7% of  all mucormy-
cosis cases[6,10]. It most commonly involves the stomach 
(57.5%), followed by colon (32.3%) and ileum (6.9%)[10]. 
This rare and opportunistic infection has been reported 
in neonates, probably due to their immature immunity, 
presenting as necrotizing enterocolitis. In published 
literature, less than 20 cases of  gastrointestinal mucor-
mycosis with colon involvement in adult patients have 
been published in the last two decades (Table 2) [10-22]. It 
also occurs in those with severe malnutrition and intrin-
sic abnormalities of  the gastrointestinal tract, including 
amoebic colitis, typhoid, pellagra and kwashiorkor[10]. 
The infection may arise from ingestion of  fungal spores 
on food or contaminated sputum. Actually, the three 
patients we have described here were also reported in an 
outbreak of  intestinal infection in our hospital[23]. They 
had sole intestinal involvement, likely due to the intake 
of  contaminated allopurinol tablets and commercially 
packaged food items[23].
A typical gastrointestinal lesion consists of  a dark ul-
cer with sharply demarcated edges and with necrosis and 
thrombosis in adjacent vessels. The infection can extend 
from the lumen of  the gut and may cause obstruction, 
perforation or bleeding. Initial presentations may be 
abdominal pain and distension, fever, and diarrhea. If  
there is extensive bowel involvement with multiple ulcers 
caused by the fungal infection, it may present with gas-
trointestinal bleeding or even visceral perforation at late 
presentation[10]. Consequently, neutropenic fever can be a 
common presenting feature of  mucormycosis, as in our 
patients. A high degree of  clinical suspicion is needed to 
diagnose this rare condition. Therefore, persistent severe 
abdominal pain in a patient with neutropenia should 
alert the clinicians to the possibility of  this invasive fun-
gal infection.
Diagnosis depends on histological examination for 
the presence of  predominantly aseptate wide hyphae 
with focal bulbous and non dichotomous branching oc-
casionally at right angles[4]. Over 94% of  sampled tissues 
also show infarction and angioinvasion on histology 
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Table 1  Taxonomic classification of the Zygomycetes
Class Order Family Genus Species causing human diseases
Zygomycetes Mucorales Mucoraceae Rhizopus R. oryzae1,2
R. microsporus var. rhizopodiformis1,2
Rhizomucor R. pusillus1,2
Mucor M. circinelloides1,2
Absidia A. corymbifera1,2
Apophysomyces A. elegans1,2
Cunninghamellaceae Cunninghamella C. bertholletiae1,2
Entomophthorales Ancylistaceae Conidiobolus C. coronatus2
Basidiobolaceae Basidiobolus B. ranarum2
1Mucormycosis: Infections caused by Mucorales; 2Zygomycosis: Infections caused by Zygomycetes (Mucorales & Entomophthorales).
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examination[24]. Though culture remains the predomi-
nant way in which one can identify fungal species, it is 
positive in only 52% of  autopsy cases and only 30% of  
surgical specimens[25]. This is because the infection may 
be localized and cannot be detected in all portions of  
the specimen submitted for culture. Nowadays there 
are no reliable serologic or skin tests for mucormycosis. 
Recently, some have attempted to improve the diagno-
sis by detecting fungal nucleic acid in the serum using 
polymerase chain reaction (PCR) or in situ hybridiza-
tion techniques[3]. As an adjuvant diagnostic tool, this 
can be used for confirming the presence of  presump-
tive organisms when histology is positive and cultures 
are negative. It may provide some guidance in selecting 
appropriate antifungal therapy when the histological 
diagnosis is undetermined. Besides pathological and mi-
crobiological diagnosis, CT/MRI scan[26] and endoscopy 
examination[11,14] have been described in the literature. 
Endoscopic features of  colonic mucormycosis have 
been reported as hemorrhagic, edematous mucosa with 
erosions, resembling endoscopic features of  ischemic 
colitis. A smooth, mushroom-like greenish fungal mass 
with a small base of  attachment to the bowel wall may 
be seen. Occasionally a black crust overlies the ulcerated 
area[11].
From a surgeon’s point of  view, the principal of  
management of  colonic mucormycosis in these severely 
immunocompromised patients largely depends on timely 
diagnosis, reversal of  the underlying predisposing condi-
tions, early surgical debridement, and rapid initiation of  
effective systemic antifungal therapy[3]. As neutropenic 
enterocolitis is the commonest cause in the neutropenic 
cancer patient, careful serial clinical observation with 
liberal use of  CT scanning is suggested[27,28]. Contrast CT 
scans may show a thickened colonic wall with decreased 
attenuation due to edema, necrosis, or a collection of  
extraluminal fluid[28]. Also, the scan may detect the pres-
ence of  a small amount of  free gas or pneumatosis in-
testinalis not visible on plain films, suggestive of  bowel 
perforation. If  the initial conservative treatment is not 
successful, including bowel rest, hydration, and broad-
spectrum antibiotics, some have advocated a more ag-
gressive surgical intervention[29-31]. As for our patients, 
they were initially managed in their medical wards for 
chemotherapy-induced neutropenic colitis; however, 
our surgical team was consulted after failed conservative 
treatment.  
In the first patient of  our series, exploratory laparot-
omy was selected for investigating suspected bowel per-
foration in view of  persistent peritoneal signs and turbid 
peritoneal fluid aspirated. However, only dilated cecum 
with edematous wall but no perforation were identified; 
the intraoperative diagnosis of  neutropenic enterocolitis 
was compatible with this finding, so that only peritoneal 
lavage was performed and conservative management was 
continued afterwards. Although the patient’s condition 
was rapidly deteriorating, no surgical intervention was 
considered in view of  multiple organ failure.
Continuing aggressive medical treatment and sup-
portive measures after surgery for neutropenic entero-
colitis have been reported, with high mortality[28]. Fungal 
neutropenic enterocolitis has been reported as fatal[32] as 
the mucormycosis is a highly angioinvasive infection, re-
sulting in extensive thrombosis and tissue necrosis, and 
antifungal agents often display poor penetration at the 
site of  infection. Removal of  as much of  the infected or 
devitalized tissue as possible while the infection is local-
ized provides the greatest benefit. In the study by Roden 
et al[6], the survival rate was 57% (51/90) for those treated 
with surgery alone and 62% (369/596) for those treated 
with some form of  antifungal therapy alone. How-
ever, the survival increased to 70% (328/470) for those 
treated with combined surgery and antifungal therapy. 
In our third patient, the diagnosis of  mucormycosis was 
confirmed pathologically soon after the first operation, 
and he began antifungal therapy immediately. Currently, 
the recommended antifungal therapy for mucormycosis 
includes amphotericin B and its liposomal preparation 
which can be delivered with reduced nephrotoxicity[3]. 
The common prophylactic antifungal agents used in neu-
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Table 2  Summary of colonic mucormycosis cases reported in the recent medical literature
Age (yr)/Sex Morbidity Location Operation Medications Outcome Ref. Yr
21/F APL Cecum Colectomy Amp B Survived [11] 1985
21/F AML Descending Hartmann Amp B Survived [12] 1986
54/F ALL Cecum Right hemicolectomy Amp B Dead [13] 1998
42/F SLE Left colon + stomach Subtotal colectomy Amp B Dead [14] 1998
35/M Liver Tx Cecum + liver Primary repair - Dead [15] 1999
53/F NHL Sigmoid + transverse Hartmann + right 
hemicolectomy
Amp B → Lip Amp + 
GMCSF
Survived [16] 2000
48/F ALL Ileocolic + liver Bowel resection Amp B → Lip Amp Dead [17] 2000
33/M Renal Tx Right colon + esophagus Graft nephrectomy Amp B + GMCSF Survived [18] 2001
65/M COAD Right colon Right hemicolectomy Amp B Survived [19] 2004
56/F ALL Ileocolic Right hemicolectomy Lip Amp Dead [20] 2005
43/F Renal Tx Cecum Right hemicolectomy Lip Amp Survived [21] 2005
58/? MS Sigmoid Hartmann - Dead [22] 2006
APL: Acute progranulocytic leukemia; AML: Acute myeloid leukemia; ALL: Acute lymphocytic leukemia; COAD: Chronic obstructive airways disease; 
SLE: Systemic lupus erythematosus; Liver Tx: Liver transplant; Renal Tx: Renal transplant; NHL: Non-Hogkin’s lymphoma; MS: Multiple sclerosis; Amp B: 
Amphotericin B; Lip Amp: Liposomal amphotericin preparation; GMCSF: Granulocyte macrophage-colony stimulating factor.
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tropenic patients (such as fluconazole and itraconazole) 
or even new agents (voriconazole and caspofungin) are 
not active against the Mucorales order in clinical and 
in vitro studies. An orally available broad-spectrum inves-
tigational triazole, posaconazole, seems to possess activ-
ity against this fungus and improves patients’ survival in 
refractory cases[33]. Furthermore, in addition to posacon-
azole treatment, another exploratory laparotomy with 
extensive small bowel resection and omentectomy was 
performed in our patient, in order to debride all infec-
tion foci. This approach has been reported as providing 
a survival advantage in the published literature[16,19,21]. 
Apart from early diagnosis, as mentioned before, cor-
rection of  any reversible predisposing factors, such as by 
rectifying diabetic ketoacidosis, withdrawing desferrox-
amine therapy or reducing the level of  immunosuppres-
sion, is an important consideration in patient manage-
ment. In neutropenic patients, resolution of  neutropenia 
is directly correlated with clinical improvement and bet-
ter outcomes[34]. Without neutrophil recovery, antifungal 
drugs are ineffective. Cytokines, such as interferon-γ 
and granulocyte macrophage-colony stimulating fac-
tor (GMC-SF), can reduce the degree and duration of  
neutropenia and subsequent infections in these patients. 
Other non-medication-based interventions, such as hy-
perbaric oxygen therapy[35] and novel iron chelators[36], 
have found limited success as an adjunctive treatment.
In summary, we report three cases of  ileocolic mu-
cormycosis presenting as acute abdomen in neutropenic 
patients which failed to respond to combined surgical 
and medical treatment. Though the new antifungal agent 
posaconazole is effective against the Mucorales order of  
fungi, timely diagnosis and adequate surgical debride-
ment are essential for the successful management of  
colonic mucormycosis.
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